Boston Scientific Deal Caps Week as Q3 Revenue Tops Estimates
PEN sits 46% above its 52-week low of $221.26.
Summary
Boston Scientific has agreed to acquire Penumbra, with the deal expected to close in early 2027 pending customary closing conditions and regulatory approvals. That takeover agreement is the dominant fact for the stock — it puts a hard floor under the shares and shifts the question from growth to deal completion. The Q3 numbers themselves were solid on the top line: revenue of $410.1 million rose 15.6% year over year and beat estimates. Profitability moved the other way, with net income down 7.8% to $42.3 million and diluted EPS down 8.5% to $1.07. This follows the October 29 release of those Q3 results and the October 20 FDA clearance of a DVT indication for the Lightning thrombectomy platform. Watch regulatory approval progress toward the early 2027 close.
At the time of this announcement, PEN was trading at $321.99 on NYSE in the Life Sciences sector, with a market capitalization of approximately $12.6B. The 52-week trading range was $221.26 to $362.41. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.